Skip to content

Unicycive Therapeutics, Inc.

UNCY

CIK 0001766140

← back to feed
Revenue (TTM)
$675K
−29.0% YoY Q1 May 2026
Net Income (TTM)
−$24.71M
+27.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.89
+70.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-4,552.7%
Q1 May 2026
Net Margin
-3,660.9%
Q1 May 2026
Free Cash Flow (TTM)
−$25.55M
Q1 May 2026
Cash
$37.37M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
26.7M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings